Rok Frlan (0000-0003-0956-5537)

Personal information

Biography

Basic information
• Address: University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, 1000 Ljubljana, Slovenia
• Phone: +386 1 4769 674
• Email: rok.frlan@ffa.uni-lj.si
• Webpage: https://www.ffa.uni-lj.si/en/news-and-information/employees/frlan-rok
• OrcidID: 0000-0003-0956-5537
Education
• 2009–2010: Postdoctoral fellowship, Université Paris Descartes, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Paris, France.
• 2005–2009: PhD, Faculty of Pharmacy, University of Ljubljana, Slovenia.
• 1998–2004: Master of Pharmacy (Uniform Master’s Study Programme), Faculty of Pharmacy, University of Ljubljana, Slovenia.
Academic and Scientific Title
• Associate Professor, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana.
Employment
• 2016–Present: Assistant Professor, Faculty of Pharmacy, University of Ljubljana.
o Main responsibilities: Teaching and research.
• 2009–2016: Postdoctoral Associate, Faculty of Pharmacy, University of Ljubljana.
o Main responsibilities: Teaching and research.
• 2005–2009: PhD Student and Research Assistant, Faculty of Pharmacy, University of Ljubljana.
o Main responsibilities: Research.
Management Functions and Skills
• Mentorship:
o 1 PhD student (mentor), 2 PhD students (co-mentor), 33 Master’s students (mentor), 17 Master’s students (co-mentor).
• Projects:
o Led 3 projects with the pharmaceutical industry (Krka and Lek).
 Development of green synthesis approaches for Sitagliptin (Lek).
 Synthesis of Valsartan in collaboration (Krka).
 Synthesis of Chitosan derivatives for dermatological application (Lek).
o Co-led 2 projects with the pharmaceutical industry (Lek).
o Successfully collaborated on European projects EUR-INTAFAR, MAREX, Orchid and Breakthrough (ongoing)
 EUR-INTAFAR: Targeting antibacterial resistance.
 MAREX: Researching marine-derived bioactive compounds.
 Orchid: Design and synthesis of new antitubercular drugs
 Breakthroug: Design of novel compounds agains Gram-negative bacteria
o ARIS projects
 2 bilateral projects funded by ARIS (France, Norway)-ongoing
 Identification of Small Molecule Inhibitors for the Development of New Antibacterial Drugs-France
 Evaluation of Academic Libraries to Develop New Antibacterial Compounds-Norway
 Currently participates in four projects:
 Breaking walls: development of D,D- and L,D-transpeptidase inhibitors
 Development of antibacterial agents targeting validated enzymes in peptidoglycan biosynthesis
 Inhibitors of bacterial biofilm formation: a novel approach to tackling bacterial resistance
 Development of new low-molecular-weight modulators of Toll-like receptors 7 and 8 for cancer immunotherapy
Project Leader’s Ability to Encourage Young Researchers
• Actively mentors graduate and PhD students, guiding them toward top-quality research.
• Engages young researchers in innovative projects, such as machine learning, green synthesis and drug design.
• Supports skill development in advanced techniques, including molecular modeling and machine learning.
Work in Expert Committees
• Member of the Slovenian Pharmaceutical Society.
• Engaged in interdisciplinary collaborations at national and international levels.
• Reviewer for ACS, MDPI
• Guest editor (2x) at Antibiotics (MDPI)
Awards
• 2016: Golden Prize for Innovation, Chamber of Commerce and Industry of Slovenia.
• 2009: Special Krka Prize for significant contributions in science, Krka
• 2004: Krka Prize for research excellence, Krka
Additional Information
• Publications: 38 research articles and reviews in journals with impact factors.
• Patents: 1 patent
• Presentations: Delivered 17 presentations at scientific conferences.
• Languages: Proficient in Slovenian (native), English (B2), and French (A2).
• Technical Expertise:
o Proficient in NMR, IR, and computer-based drug design.
o Skilled in molecular modeling programs (Zinc, Schrödinger, OpenEye), Python.

Activities

Collapse all

University of Ljubljana: Ljubljana, Aškerčeva 7, 1000 Ljubljana, SI

2006-10-01 to present (Faculty of pharmacy)

Employment

Rok Frlan

https://orcid.org/0000-0003-0956-5537

Personal information

Emails & domains

Verified email domains

Websites & social links

Other IDs

Countries

Biography

Activities

Employment (1)

University of Ljubljana: Ljubljana, Aškerčeva 7, 1000 Ljubljana, SI

Education and qualifications (1)

University of Ljubljana: Ljubljana, SI

Funding (6)

Identification of low molecular weight inhibitors for the development of new antibacterial drugs

Bacterial Biofilm Formation Inhibitors: A Novel Approach to Combat Antimicrobial Resistance

Breaking the Walls: Development of Inhibitors of D,D- and L,D-Transpeptidases

Development of novel small molecule Toll-like receptors 7 and 8 modulators for cancer immunotherapy

Development of antibacterial compounds targeting validated enzymes in peptidoglycan biosynthesis

Medicinal chemistry - drug design, synthesis and evaluation

Works (24)

Development of novel aza-stilbenes as a new class of selective MAO-B inhibitors for the treatment of Parkinson’s disease

Correction to “Identification of a Novel Structural Class of HV1 Inhibitors by Structure-Based Virtual Screening”

Identification of a Novel Structural Class of HV1 Inhibitors by Structure-Based Virtual Screening

Using Subcritical Water to Obtain Polyphenol-Rich Extracts with Antimicrobial Properties

Navigating the Chemical Space of ENR Inhibitors: A Comprehensive Analysis

Mur ligase F as a new target for the flavonoids quercitrin, myricetin, and (–)-epicatechin

Inhibition of MurA Enzyme from Escherichia coli by Flavonoids and Their Synthetic Analogues

Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an <i>in-house</i> compound library

Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?

An Evolutionary Conservation and Druggability Analysis of Enzymes Belonging to the Bacterial Shikimate Pathway

Mur ligases inhibitors with azastilbene scaffold: Expanding the structure-activity relationship

Inhibition of MurA Enzyme from Escherichia coli and Staphylococcus aureus by Diterpenes from Lepechinia meyenii and Their Synthetic Analogs

Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity

A New Cell-Based AI-2-Mediated Quorum Sensing Interference Assay in Screening of LsrK-Targeted Inhibitors

Efficient and Straightforward Syntheses of Two United States Pharmacopeia Sitagliptin Impurities: 3-Desamino-2,3-dehydrositagliptin and 3-Desamino-3,4-dehydrositagliptin

Identification of novel inhibitors of the ABC transporter BmrA

Application of the N-Dibenzyl Protective Group in the Preparation of β-Lactam Pseudopeptides

Discovery of D-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation

Evaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use

Design, Synthesis, and Evaluation of Novel Tyrosine‐Based DNA Gyrase B Inhibitors

Nucleophilic Opening of an Epoxide by a Masked Glycine Anion Equivalent: A Route to C-Glycosyl Amino Acids

Cobalt-Catalyzed Cross-Coupling of Grignards with Allylic and Vinylic Bromides: Use of Sarcosine as a Natural Ligand

D-Glucosamine in iron-catalysed cross-coupling reactions of Grignards with allylic and vinylic bromides: application to the synthesis of a key sitagliptin precursor

Design and Synthesis of Novel UDP-Mur-NAc, UDP-Mur-NAc-L-Ala and UDP-Mur-NAc-L-Ala-D-Glu mimetics

Peer review (14 reviews for 8 publications/grants)